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Abstract
There has been debate on the best treatment regimen for CAP, whether to start 
treatment with β-lactams, β-lactam β-lactamase inhibitor, macrolides, a combina-
tion of the earlier or quinolones, among other less commonly used agents. In this 
review, an attempt to examine some data on the utilization and importance of 
respiratory quinolones in the treatment of CAP, and to examine whether quino-
lones are the same in clinical and microbiological efficacy, shall we stick to seven 
days of treatment versus shorter duration without compromising outcome? Are 
resistance patterns for respiratory quinolones the same, and are there savings as-
sociated with using some respiratory quinolones over others? Moreover, are there 
any differences in mortality when examined as a treatment end-point, and if there 
is any differences in speed of recovery for different respiratory quinolones? Do we 
need to incorporate pharmacokinetics/pharmacodynamics principles in the treat-
ment of CAP, and how to dose anti-infective agents in CAP, opposed to leaving 
treatment-doses for minimum inhibitory concentration alone?
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Introduction
Community acquired pneumonia conventionally classified 
into three severity levels: outpatient pneumonia, non-ICU 
in-patient pneumonia and ICU-pneumonia. Microorganisms 
that are prevalent in the three severity levels are Strepto-
coccus pneumoniae and Hemophilus influenzae, meanwhile 
Mycoplasma pneumoniae, Chlamydophila pneumoniae and 
respiratory viruses add to the outpatient CAP. Staphylococ-
cus aureus and gram–negative bacilli contribute as a major 
burden in ICU-CAP, while inpatient non ICU-CAP to a large 
extent shared by aspiration microorganisms and legionella 
species, the later contributes as well to ICU-CAP. (1)
Resistance among respiratory pathogens has been escalating; 
Streptococcus pneumoniae harbors penicillin resistance, and 
has been increasing, where lately isolates from several studies 
showed absolute resistance between 14.6-21.5% with inter-
mediate resistance of about 12.7 - 17.9%. (2) Arab coun-
tries share the same phenomena of high resistance patterns 
among pneumococci, where in Kuwait 55% of pneumococ-
ci were penicillin-resistant (intermediate 46% and full 9%). 
Fourty-one percent were sulfamethoxazole-trimethoprim-re-
sistant, 9% resistant to cefotaxime and ceftriaxone, 15% to 
amoxycillin-clavulanate, 17% to cefuroxime, 77% to cefaclor, 
and 14% to clindamycin. In United Arab Emirates the qui-
nolones ofloxacin- and ciprofloxacin-resistant pneumococci 
were reported, in addition to penicillin- and cephalosporins-
resistant strains. In Yemen, Egypt, Qatar and Saudi Arabia 
penicillin-resistant pneumococci also widely range in their 
susceptibility patterns from 8 - 78%. In some African coun-
tries, pneumococcus penicillin resistance is about 50% and 
up to 80% in Japan, penicillin resistant pneumococci acquire 
other antimicrobials’ resistance like macrolides resistance. 
Moreover, pneumococci show multiple resistance patterns 
against antimicrobials. (2, 3, 4, 5,)
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 H. Influenzae used not to harbor significantly β–lactamases 
in clinical specimens before 1972; lately, β-lactamases con-
tribute to large burden in Hemophilus. (6) Resistance in H. 
influenzae to many antimicrobial agents increased dramati-
cally, with increased MIC’s from 0.25 - 0.5 µg/ml in the pre 
β-lactamases era to over 32 mg/l in the post β-lactamases 
era, ampicillin susceptibility dropped to about 70% and TMP-
SMX to less than 80% susceptibility. Hitherto, quinolones 
maintain excellent susceptibilities toward respiratory patho-
gens, namely gemifloxacin which demonstrates impressive 
low MIC’s against clinical isolates of Streptococcus pneumoni-
ae (MIC90 = 0.016 – 0.06), Hemophilus influenzae (MIC90 < 
0.0008 – 0.06), Moraxella catarrhalis (MIC90 = 0.008 – 0.3), 
Chlamydia pneumoniae (0.25) and Legionella spp. (0.125). 
(6, 7, 8)
Diagnosis 
Due to the changing resistance patterns in respiratory patho-
gens, diagnosing the infecting pathogen is of utmost impor-
tance in approaching CAP, this holds true for all risk catego-
ries, especially those with severe illnesses like ICU-CAP, failure 
of previous antimicrobial regimen, cavitary infiltrate, leucope-
nia, COPD, asplenia, recent travel, active alcohol abuse and 
patients with pleural effusion. (9) In spite of that, the recov-
ery of suspected respiratory pathogens e.g. pneumococcus 
in adults’ sputum with CAP has been decreasing. Though 
examining expectorated sputum is a simple diagnostic proce-
dure, nevertheless its benefit in revealing a diagnosis, when 
properly processed is up to 70%, especially in CAP due to 
S. pneumoniae, S. aureus , S. pyogenes , H. influenza and 
gram-negative bacilli, an organism obtained from sputum 
correlates with the diagnosis in 93% of times. (10) Other 
diagnostic methods may be used safely mostly in inpatient 
CAP, like trans-thoracic needle aspiration which is disfavored 
by practicing physicians and patients, bronchoscopy though 
it is uncommonly used in CAP, but it is helpful, especially 
when it is used with protected brush specimen using culture 
of threshold 103 CFU /ml . Other diagnostic tests of great 
help are urinary antigens detection, where it helps in diagnos-
ing CAP due to legionnairs disease that accounts for about 
2 - 6 % of CAP in some countries, pneumococcal antigen 
may be used, though its sensitivity and specificity are less in 
patients with non-bacteremic CAP. The need to have an ac-
curate microbiological diagnosis in CAP is compelling because 
studies clearly showed that pathogen-directed treatment was 
superior to empiric treatment when mortality was measured 
as an endpoint, as well as length of hospital stay and clinical 
failure. (10, 11) 
The Quinolones 
Quinolones are useful anti-infective agents, with wide scale 
acceptance among physicians for their spectrum against re-
spiratory bacteria, easiness of administration and lower side 
effects profile compared with other antimicrobials, their use 
has been increasing over the last decades in patients 18 years 
or older. On the other hand, like other antibacterial agents, 
the potential of some respiratory bacteria to develop quino-
lones resistance is there, seeing that ciprofloxacin use esca-
lates. Prevalence of ciprofloxacin-resistant strains increased 
over years in many parts of the world, with increased degrees 
of resistance i.e. higher in prevalence and with higher MIC’s, 
though it remained low when compared with other anti-
infective classes. (12, 13)
Quinolones nucleus modification gave rise to new agents, 
with variable PK/PD and antimicrobial properties, this lead 
to their classification into four generations for a better un-
derstanding. Quinolones are classified into four generations 
based on their in vitro activity; first generation that include 
parent compound of limited clinical use such as nalidixic acid, 
second generation; include popular agents used for many in-
fections i.e. ciprofloxacin, levofloxacin and ofloxacin; the third 
generations like sparfloxacin, gatifloxacin and grepafloxacin, 
and the fourth generations like moxifloxacin, gemifloxacin 
and trovafloxacin. (14)
Since their introduction in the late 1990’s respiratory qui-
nolones demonstrated their benefit by clearly showing that 
their 30-days-mortality is less than other agents used in 
the treatment of CAP, like β-lactam/β-lactamase-inhibitor 
plus macrolide or an aminoglycoside plus another agent. 
The second-generation cephalosporins plus macrolides, and 
non-pseudomonal third-generation cephalosporins plus mac-
rolides almost has similar effect on the 30-days-mortality 
like quinolones mono-therapy (Figure 1). Adjusted mortality 
among patients initially treated with respiratory fluoroquino-
lones and the other two regimens became significantly lower 
beginning 2, 3, and 7 days after hospital admission, respec-
tively. (9, 15, 16). A number of international recommenda-
tions for CAP treatment were published over the last years 
e.g. IDSA guidelines, where respiratory fluoroquinolones are 
recommended among first-line agents; like in outpatient CAP, 
or as first line agents as in inpatient non-ICU CAP, and as first 
agent in previous both categories when patients are β-lactam 
allergic. In severe ICU-CAP requiring admission, ciprofloxacin 
and levofloxacin are the preferred agents. On the other hand, 
in the British Thoracic Society guidelines for 2009 discourages 
the use of respiratory quinolones as first line treatment choice 
in favor of amoxicillin/clavulanate, because of increased inci-
dence of MRSA and CDI associated with their excessive use, 
and because RFQ were found as good as other agents in low 
severity CAP. (17)
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Adherence to guidelines is encouraged as the total manage-
ment-related effect is in its favor, though in a study, it showed 
increased utilization of chest X-rays, increased prescription of 
antimicrobials with relatively less diagnosis of CAP. Adherence 
to guidelines showed in a study of 780 patients from Barce-
lona favorable effects that outweigh some previous caveats; 
it clearly showed decrease in mortality (p = <0.001) and de-
crease in length of hospital stay (p = 0.004). Bearing in mind 
that guidelines on CAP treatment should be considered with 
the prevalent microorganism and susceptibility trends for each 
part of the world; it is important to be familiar with local re-
sistance patterns, and microbiology results, all should be used 
to narrow the choice of suitable antimicrobials. (16, 18, 19)
Quinolones; MIC’s and resistance
Quinolones are potent agents, against bacteria encountered 
mostly in lower, as well as upper respiratory infections, with 
low MIC’s. The fourth generations RFQ are the most potent 
agents among quinolones in activity against pneumococci, 
and other respiratory pathogens. The least effective quino-
lone is ciprofloxacin where susceptible pneumococci have rela-
tively elevated MIC’s, and they rank highest for resistance in 
pneumococci, about 1,8%, though resistance detected rarely 
among RFQ’s, but in levofloxacin is about 0.7%, gatifloxacin 
0.6%, and the least is for moxifloxacin and gemifloxacin where 
resistance prevalence is 0.3% and 0.1% respectively. (20, 21)
The activity of RFQ’s are not affected by pneumococci pat-
terns of penicillin resistance, whether susceptible, intermedi-
ate or resistant. On the other hand, these patterns adversely 
affect susceptibilities and cause elevated MIC’s among mac-
rolides and β-lactams, which may make them clinically not 
useful to a large extent. Challenging RFQ’s against ciproflox-
acin-resistant pneumococcus strains showed that the fourth 
generation RFQ still maintain low MIC’s compared with the 
second generation RFQ like levofloxacin. (22) Furthermore, 
testing levofloxacin-susceptible (Figure 2A)and levofloxa-
Figure 1. Independent associations 
between initial antimicrobial therapy 
and 30-day-mortality among different 
antimicrobial regimens used for the 
treatment of CAP. Third generation non-
pseudomonal parenteral cephalosporins 
used as a reference to calculate hazard 
ratios and assigned a ratio of one. The 
middle curve is the hazard ratio with 
the other two lines for 95% Confidence 
Interval. (Adapted from reference 16)
LL: lower bound for the confidence 
interval
UL: upper bound for the confidence 
interval
βL/βLI: beta-lactamase, beta-lactamase 
inhibitor
Figure 2.  Comparative activities of four fluoroquinolones against (A) levofloxacin-susceptible S. pneumoniae clinical isolates and 
(B) levofloxacin-resistant S. pneumoniae clinical isolates. (Adapted from reference 23) 
MIC: minimum inhibitory concentration N: number of tested pneumococci.
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cin-resistance (Figure 2B) pneumococci against other RFQ 
showed clearly that gemifloxacin and clinafloxacin are the 
most potent agents maintaining low MIC’s in pneumococci, 
and adequate clinical effect on those levofloxacin-susceptible 
and -resistant pneumococci (MIC ≥ 8 µg/ml). In this regard, 
levofloxacin-resistant pneumococci do not preclude using 
gemifloxacin and clinafloxacin in their treatment, consider-
ing the other overall data on both agents are available, like 
their PK/PD and clinical use studies, as is the case with gemi-
floxacin. (23)
Resistance and its evolution among RFQ
Streptococcus pneumoniae acquire resistance against quino-
lones through mutations in the genes encoding for the target 
enzymes (topoisomerases) located in quinolones resistance 
determining region (QRDR) with genotypes gyrA, gyrB, parC, 
and parE; resistance occur in these loci when amino acids 
substitution occur at different loci. The “first-step” occur 
when pneumococci acquire parC mutation (topoisomerase 
IV) which occurs fairly frequent (～1/107 of pneumococcal col-
onies), this acquisition increases resistance to about four-folds 
in levofloxacin MIC, and this occurs when pneumococci come 
under ciprofloxacin-exposure pressure. Higher MIC’s occur 
and resistance worsen should a second-step mutation oc-
curs in another active site i.e. gyrA (topoisomerase II). When 
combined parC and gyrA occur, resistance to gatifloxacin, 
levofloxacin and trovafloxacin become at or above resistance 
breakpoints defined by CLSI, but not to gemifloxacin and 
clinafloxacin, gemifloxacin with its marked potency against 
wild type and quinolone-resistant mutants may ensue from 
greatly stabilizing the cleavable complexes with the target 
enzymes, and possibly clinically evident. Resistance may oc-
cur to a lesser extent through mutations in parE and gyrB, 
resistance can also be mediated by active efflux, although 
its role in contributing to resistance in the newer RFQ’s is 
unclear. (2, 23, 24, 25)
Each step in resistance evolution diminishes quinolones sus-
ceptibility by 4-8 folds among pneumococci. Consequently, 
if one quinolones MIC was lower than the other as it oc-
cur in e.g. levofloxacin compared with ciprofloxacin respec-
tively, then one mutation may put ciprofloxacin at or above 
susceptibility zone, while levofloxacin maintains its potency 
against pneumococci, unless more than one mutation occur. 
However another pattern of quinolones resistance occurs, 
when pneumococci acquire one-step mutation with elevation 
in MIC, this will not affect some quinolones, like gemifloxa-
cin and clinafloxacin. Other agents may suffer from more 
than one mutation, thus come in the full resistance zone. 
Depending on quinolone potency, number and type of mu-
tations in pneumococci may acquire; resistance may assume 
a cross-resistance or divergent (dichotomous) patterns. (26) 
This phenomena may be helpful in explaining the inclusions 
of mutants, and prevention of resistance by some potent 
quinolones, referred to as mutant prevention concentration. 
Quinolones that may account for mutants coverage in their 
spectrum are the fourth generation RFQ, where restriction for 
mutant selections was found most potent in gemifloxacin fol-
lowed by moxifloxacin then trovafloxacin, gatifloxacin, grepa-
floxacin and the least with levofloxacin. (27, 28, 29, 30, 31)
In an elegant trial carried out by M. Ryback and colleagues, 
the potential for resistance development were tested for gati-
floxacin, gemifloxacin, levofloxacin and moxifloxacin (Figure 
3). For that purpose, he designed a simulation model, keeping 
in a compartment 108.5 –109 log10 CFU/ml of Streptococcus 
pneumoniae ATCC 49619 and BSP2443, both strains did not 
have mutations for quinolones resistance in the QRDR’s i.e. 
no parC, parE, gyrA and gyrB as well as no efflux mechanism 
for resistance. Antimicrobials were infused into the compart-
ment to simulate the pneumococcal target ƒAUC/MIC. Free 
quinolones (protein unbound) levels in the compartment was 
calculated based on manufacturers’ recommendations for 
quinolones protein binding (20% for gatifloxacin, 60% for 
gemifloxacin, 30% for levofloxacin and 40% for moxifloxa-
cin). Within duration of up to 96 hours, pneumococcal strains 
were constantly exposed to each quinolone independently. It 
was found that the evolution of resistance was observed to 
start earlier in levofloxacin model and progressively increased, 
thus, leading to a significant difference in the evolution of 
pneumococcal resistant mutants in comparison with the 
other quinolones e.g. moxifloxacin (p = 0.0001), gemifloxa-
cin (p = 0.001) as well as gatifloxacin (p = 0.001). Ryback 
and colleagues concluded that clinical doses of gatifloxacin, 
gemifloxacin, and moxifloxacin exceed the ƒAUC/MIC resis-
tance breakpoint against wild-type pneumococci and that the 
exposure breakpoints differ among levofloxacin, gatifloxacin, 
gemifloxacin, and moxifloxacin. Consequently, in the preven-
tion of resistance, moxifloxacin = gemifloxacin > gatifloxacin 
> levofloxacin. This may be due to different structures qui-
nolones have within the same class. (38)
Pharmacokinetics/Pharmacodynamics of 
quinolones
Dr. Harry Eagle started in the nineteen-forties to -fifties the 
concept of pharmacokinetics/pharmacodynamics (PK/PD), but 
his work was not appreciated until many years later. From the 
late 1970s through the early 1990s, PK/PD concepts were re-
discovered and expanded upon thorough elegantly designed 
rodent experiments conducted by Dr. William Craig. (32) Our 
understanding of PK/PD largely improved in the last few de-
cades; types of bacterial killing came from work on mice 
models, later translated and studied in humans. Several types 
of bacterial killing was recognized; time-dependent which 
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is dependent on how long antimicrobials levels should be 
kept in patients’ serum above the antimicrobial MIC, this is 
referred to as time-dependent killing and is predicted by T 
>MIC, β-lactams are an example for this type (figure 4A). 
Concentration-dependent bacterial killing depends solely on 
the antimicrobial concentration in patients’ serum, even if 
during the rest of dosing interval the antimicrobial serum level 
is lower than the required MIC, it is predicted by Cmaximum/
MIC, an example of this type of bacterial killing are amino-
glycosides (Figure 4B). Quinolones adopt what is described 
as mixed concentration-dependency with time-dependency 
consideration i.e. exposure-dependency, this is predicted by 
how much of drug is in the patients’ serum over time, this 
predicted by area under the curve divided by MIC i.e. AUC/
MIC (Figure 4C). (32, 33,) The predicted AUC/MIC for quino-
lones and respiratory pathogens were determined and clini-
cally correlated with treatment success and microbiological 
eradication to be somewhere 30-50 for pneumococci, for 
gram-negative microorganism 125-250, and in the immuno-
compromized a ratio of at least 100 is required. (32,34) Also 
mortality was found to become less as we reach above PK/
PD break points on treating serious bacterial infections i.e. 
≥ 100, and not relying solely on the MIC’s of the infecting 
pathogen. (33)
There have been some debates on whether the free drug 
area under the curve over minimum inhibitory concentration 
ƒAUC/MIC or total one should be considered in the interpre-
tation of treatment PK/PD target attainment levels. Quino-
lones especially the fourth generation quinolones attain PK/
PD targets, mostly gemifloxacin, where it attained ƒAUC/MIC 
of > 100 and total AUC/MIC of over 250. Other respiratory 
quinolones like moxifloxacin marginally attain the free break-
point and totally reaches over 150. Levofloxacin 750 mg/day 
attain the 30 breakpoint, which is the minimum target to at-
tain to have a sizable activity against pneumococci. Clinically, 
if dosing attain AUC/MIC < 25 or Cmax/MIC < 3, the clinical 
success rate reach 57%, AUC/MIC 25-100 or Cmax/MIC 3-12 
the success become 88.5%, while attaining AUC/MIC > 100 
or Cmax/MIC >12 clinical success rise up to 99%, showing a 
clear evidence of the PK/PD target-attainment application in 
patients care. (35,36, 37)
Quinolones in Clinical Practice
Quinolones won their reputation due to ease of administra-
tion, effectiveness in treating respiratory pathogens and low 
side effects profile. In a trial of severe pneumococcal pneu-
monia requiring ICU admission, the goal was to evaluate the 
outcome of patients with severe CAP, focusing on the impact 
of levofloxacin versus ofloxacin or ciprofloxacin; either was 
used with a beta-lactam antibacterial. All pneumococci were 
penicillin-susceptible. The 15 days survival in CAP patients 
treated with levofloxacin and beta-lactam were significantly 
better than the older quinolones ofloxacin or ciprofloxacin 
and beta-lactams (p = 0.031). (39)
Figure 3.  Schematic representation of the four tested quinolones in a simulation model to assess the induction of resistant mutants 
by continuously exposing pneumococci up to 96 hours. Pneumococci were exposed to antimicrobials concentrations as 
recommended by the manufacturer based on protein binding. The complimentary non-resistant curve for each quinolone-
induced mutant curve is not showing here for simplicity. (Adapted from reference 38)  
ƒAUC: free area under the curve 
MIC: minimum inhibitory concentration
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In another study evaluating recovery and efficacy for moxi-
floxacin use versus levofloxacin in elderly patients ≥ 65 years 
old after 5–21 days of completion of therapy. There was no 
Statistical significant difference in both study arms, whether 
looking at mild-moderate versus severe CAP, or looking at 
age group 65 to ≤ 75 years old versus ≥ 75 years old, as tested 
by P-value and confidence intervals. Nevertheless, there was a 
significant difference between moxifloxacin and levofloxacin 
in the speed of recovery in favor of moxifloxacin (p = 0.01), 
an effect is well appreciated especially in the elderly popula-
tion with CAP. (40)
Levofloxacin was compared in 750 mg/day dose for 5 days 
with 500 mg/day for 10 days in the treatment of mild-to-
severe CAP. Primary endpoints were clinical efficacy and mi-
crobiological efficacy in the clinically evaluable population. 
The clinical success rates were 92.4% for the 750-mg group 
and 91.1% for the 500-mg group (95% confidence inter-
val, - 7.0 to 4.4). Microbiologic eradication rates were 93.2% 
and 92.4% in the 750-mg and 500-mg groups, respectively. 
Levofloxacin 750 mg/day short course found as effective as 
500 mg/day long course, shorter courses and higher doses 
of levofloxacin may have had accounted better for mutants 
coverage, with better compliance. (41)
In a randomized multicenter double-blind study including 469 
per protocol patients (PPP) split into two arms, gemifloxacin 
was examined for efficacy and safety, prescribed for 5 and 
7 days in the treatment of outpatient mild-moderate CAP. 
Clinical resolution at follow-up was 95% and 92% for 5 and 
7 day treatments respectively (95% CI -1.48 to 7.42), and 
at the end of therapy was 96% for both regimens (95% CI 
-3.85 to 3.42). Bacteriological response rates in at the end 
of therapy were 94% and 96% a t 5 and 7 days regimen 
respectively (95% CI -8.27 to 3.25) and 91% for both groups 
at follow-up (95% CI –6.89 to 7.93). Radiological success in 
PPP at follow-up was 98% and 93% in 5 and 7 day groups 
respectively (95% CI 0.35, 7.91). Clinical, bacteriological and 
radiological responses were similar in the 5 and 7 days in 
the PPP at the end of treatment and follow up assessment 
endpoints. Side effects were less with the 5 days course, 
and significantly so with skin rash (p = 0.04). (42). In a meta 
analysis of randomized controlled trials, LIU You-ning and 
Falagas et al, evaluated the comparative effectiveness and 
safety of gemifloxacin when used in CAP and AECB. Gemi-
floxacin was compared with other quinolones in 5 trials, and 
compared with β-lactams and/or macrolides in 5 trials, involv-
ing 3940 patients. Overall, the treatment success was higher 
for gemifloxacin when compared with other antibiotics odds 
Figure 4. Graphical representation of PK/
PD bacterial killing-patterns by several 
antimicrobials according to  
(A) Time-dependent killing and examples 
of antimicrobials that follow this pattern, 
(B) Concentration-dependent killing and 
examples of antimicrobials that follow this 
pattern, and (C) The exposure dependent 
(Mixed pattern) killing and examples of 
antimicrobials that follow this pattern 
(Adapted from reference 32).
MIC: minimum inhibitory concentration.
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ratio (1.39, 95% CI 1.15 – 1.68) in ITT patients, and (1.33, 
1.02–1.73) in clinically evaluable patients. No significant dif-
ference was found between gemifloxacin and comparator in 
microbiological success (1.19, 0.84–1.68) or all-cause mortal-
ity (0.82, 0.41–1.63). The total adverse events were similar for 
gemifloxacin when compared with other quinolones (0.89, 
0.56–1.41), while lower when compared with β-lactams and/
or macrolides (0.71, 0.57–0.89). Gemifloxacin was associated 
with fewer cases of diarrhea and more rashes compared with 
other antibiotics (0.66, 0.48–0.91), and (2.36, 1.18–4.74) re-
spectively. This study suggested that gemifloxacin 320 mg 
daily is equivalent or superior to other approved antibiotics 
in effectiveness and safety for CAP and AECB including qui-
nolones comparators i.e. trovafloxacin and levofloxacin. Rash 
represents potential limitation of gemifloxacin. However, it 
was found to have similar microbiological response and all-
cause mortality like other quinolones. (43)
In an analysis evaluating hospital visits and costs following 
outpatient treatment of CAP with levofloxacin or moxifloxacin 
conducted between 2004 -2007, where subsequent 30-day 
risk of pneumonia-related hospital visits and 30-day health 
care costs were evaluated, 6352 paired matches were evalu-
ated. Levofloxacin treatment was associated with 35% reduc-
tion in the odds of pneumonia-related hospital visits (odds 
ratio = 0.65, P = 0.004), lower per-patient costs for pneumo-
nia-related hospital visits ($102 vs. $210, P = 0.001), lower 
pneumonia-related total costs ($363 vs. $491, P < 0.001), and 
lower total costs ($1308 vs. $1446, P < 0.001). (44) In a similar 
retrospective analysis, levofloxacin 750 mg/day intravenously 
versus moxifloxacin 400 mg/day intravenously were used as 
treatment in patients with CAP for the first 3 of their hospital 
stay. Levofloxacin-treated patients found to have a shorter 
mean hospital stay compared with moxifloxacin-treated pa-
tients (5.8 vs. 6.4 days; least squares mean difference = 0.54 
days; p = 0.020). Hospitalization costs were also lower for the 
levofloxacin-treated patients (least squares mean difference 
= US$129; p = 0.753), and complications were similar. (45)
In another retrospective study evaluating intravenous moxi-
floxacin  400 mg/day and  Levofloxacin  750 mg/day, among 
hospitalized patients with CAP in USA. A comparative analysis 
of length of stay and total costs as a primary outcome mea-
sure, treatment consistency; defined as no additional intrave-
nous moxifloxacin or levofloxacin after ≥1 day off study drug, 
no switch to another intravenous antibiotic and no addition 
of another intravenous antibiotic as a secondary outcome 
measure. In the initial analysis, length of hospital stay and 
cost was greater with moxifloxacin (p = 0.0001), however on 
propensity matching analysis, well-matched for demographic, 
clinical, hospital and payer characteristics, 1300 pair-patients 
were compared, there was no significant difference in the 
mean length of hospital stay (p = 0.462) and total cost (p = 
0.476). Furthermore, treatment consistency was better with 
moxifloxacin than levofloxacin before propensity analysis (p = 
0.048) and after propensity analysis (p = 0.002). (46)
In conclusion
Penicillin resistant S. pneumoniae should always be consid-
ered in the management of CAP, and failing to account for 
its treatment may have grave consequences. Based on sev-
eral surveillance studies, RFQ resistance among respiratory 
pathogens is low and stable so far, lowest for the fourth 
generation quinolones i.e. gemifloxacin and moxifloxacin. Re-
spiratory pathogens that are resistant to β-lactams and old 
generation quinolones do not preclude treating them with 
newer RFQ. As observed in the previous studies the level 
of resistance is different among various quinolones, and the 
potential to induce resistance is also different, therefore, qui-
nolones are not equal and should not be used interchange-
ably. In CAPRIE study, it was demonstrated that the speed 
of recovery in treating CAP in the elderly occurs faster with 
the fourth generation quinolones i.e. moxifloxacin compared 
to the second-generation quinolones i.e. levofloxacin, and 
when using the fourth-generation for CAP treatment, physi-
cians were more consistent. Cost savings is another point 
that results from quinolones use in CAP. So far, in bedside 
medicine, no differences were clearly demonstrated among 
respiratory quinolones when employed in the treatment of 
CAP, studies may be needed to further clarify this point. Fur-
thermore, their liberal use have caused some drawbacks like 
increasing prevalence of MRSA, VRE, quinolone-resistant, 
ESBL-producing organisms and Clostridium difficile gastroin-
testinal infection. (47)
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